Wing-Kai Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wing-Kai Chan has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Pan-Chyr Yang
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
11 shared publications Hsuan-Yu Chen
Kang-Yi Su, Hsuan-Yu Chen, and Ker-Chau Li, Institute of Statistical Science, Academia Sinica; James Chih-Hsin Yang, Wing-Kai Chan, Jin-Yuan Shih, and Pan-Chyr Yang, National Taiwan University Hospital; Kang-Yi Su, Min-Liang Kuo, Bing-Ching Ho, and Sung-Liang Yu, National Taiwan University; Gee-Chen Chang, National Yang-Ming University, Taipei; and Gee-Chen Chang, Taichung Veterans General Hospital, Taichung, Taiwan
6 shared publications- Ang Yuan
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
5 shared publications - Jeremy J. W. Chen
Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan
5 shared publications Kuang Y. Chen
Institute of Biomedical Sciences, Academia Sinica, Taiwan and Cancer Center, Veterans General Hospital‐Taipei, Taiwan
5 shared publicationsGee-Chen Chang
Kang-Yi Su, Hsuan-Yu Chen, and Ker-Chau Li, Institute of Statistical Science, Academia Sinica; James Chih-Hsin Yang, Wing-Kai Chan, Jin-Yuan Shih, and Pan-Chyr Yang, National Taiwan University Hospital; Kang-Yi Su, Min-Liang Kuo, Bing-Ching Ho, and Sung-Liang Yu, National Taiwan University; Gee-Chen Chang, National Yang-Ming University, Taipei; and Gee-Chen Chang, Taichung Veterans General Hospital, Taichung, Taiwan
4 shared publications
Latest Publications
- 1 July 2014
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 20 (4) , 371-376
Intrapleural minocycline pleurodesis for the treatment of primary spontaneous pneumothorax
The role of chemical pleurodesis in the treatment of primary spontaneous pneumothorax remains unclear. According to current practice guidelines, chemical pleurodesis is reserved for patients who are unable or unwilling to have surgery. Some recent studies showed that intrapleural minocycline pleurodesis could decrease the rate of pneumothorax recurrence, when used either as the initial treatment for simple pneumothorax after successful aspiration and drainage or as an adjuvant treatment for complicated or recurrent pneumothorax following thoracoscopic surgery. The purpose of this review is to discuss the current available evidence on intrapleural minocycline pleurodesis for the treatment of primary spontaneous pneumothorax. In a recently published prospective, randomized controlled trial, additional minocycline pleurodesis following simple aspiration and drainage was a well tolerated and more effective initial treatment for a first episode of primary spontaneous pneumothorax than simple aspiration and drainage alone. Other prospective, randomized controlled trials showed that additional minocycline pleurodesis after thoracoscopic treatment was a well tolerated and convenient procedure which can reduce the rate of ipsilateral recurrence of primary spontaneous pneumothorax. Intrapleural minocycline pleurodesis can be considered an adjunct to standard treatment of primary spontaneous pneumothorax, after either simple aspiration and drainage or after thoracoscopic surgery.
- 1 July 2014
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 20 (4) , 371-376
Intrapleural minocycline pleurodesis for the treatment of primary spontaneous pneumothorax
The role of chemical pleurodesis in the treatment of primary spontaneous pneumothorax remains unclear. According to current practice guidelines, chemical pleurodesis is reserved for patients who are unable or unwilling to have surgery. Some recent studies showed that intrapleural minocycline pleurodesis could decrease the rate of pneumothorax recurrence, when used either as the initial treatment for simple pneumothorax after successful aspiration and drainage or as an adjuvant treatment for complicated or recurrent pneumothorax following thoracoscopic surgery. The purpose of this review is to discuss the current available evidence on intrapleural minocycline pleurodesis for the treatment of primary spontaneous pneumothorax. In a recently published prospective, randomized controlled trial, additional minocycline pleurodesis following simple aspiration and drainage was a well tolerated and more effective initial treatment for a first episode of primary spontaneous pneumothorax than simple aspiration and drainage alone. Other prospective, randomized controlled trials showed that additional minocycline pleurodesis after thoracoscopic treatment was a well tolerated and convenient procedure which can reduce the rate of ipsilateral recurrence of primary spontaneous pneumothorax. Intrapleural minocycline pleurodesis can be considered an adjunct to standard treatment of primary spontaneous pneumothorax, after either simple aspiration and drainage or after thoracoscopic surgery.
- 1 July 2013
- Published by Elsevier in The Lancet
- Vol. 382 (9888) , 203-4
Pleurodesis for primary spontaneous pneumothorax - authors' reply.
- 1 July 2013
- Published by Elsevier in The Lancet
- Vol. 382 (9888) , 203-4
Pleurodesis for primary spontaneous pneumothorax - authors' reply.
- 1 April 2013
- Published by Elsevier in The Lancet
- Vol. 381 (9874) , 1277-1282
Simple aspiration and drainage and intrapleural minocycline pleurodesis versus simple aspiration and drainage for the initial treatment of primary spontaneous pneumothorax: an open-label, parallel-group, prospective, randomised, controlled trial
- 1 April 2013
- Published by Elsevier in The Lancet
- Vol. 381 (9874) , 1277-1282
Simple aspiration and drainage and intrapleural minocycline pleurodesis versus simple aspiration and drainage for the initial treatment of primary spontaneous pneumothorax: an open-label, parallel-group, prospective, randomised, controlled trial
- Top Cited Papers
- 1 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (4) , 433-440
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Purpose: Patients with non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)–activating mutations have excellent response to EGFR tyrosine kinase inhibitors (TKIs), but T790M mutation accounts for most TKI drug resistance. This study used highly sensitive methods to detect T790M before and after TKI therapy and investigated the association of T790M and its mutation frequencies with clinical outcome. Patients and Methods: Direct sequencing, matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) and next-generation sequencing (NGS) were used to assess T790M in the following two cohorts of patients with NSCLC: TKI-naive patients (n = 107) and TKI-treated patients (n = 85). Results were correlated with TKI treatment response and survival. Results: MALDI-TOF MS was highly sensitive in detecting and quantifying the frequency of EGFR-activating mutations and T790M (detection limits, 0.4% to 2.2%). MALDI-TOF MS identified more T790M than direct sequencing in TKI-naive patients with NSCLC (27 of 107 patients, 25.2% v three of 107 patients, 2.8%, respectively; P < .001) and in TKI-treated patients (before TKI: 23 of 73 patients, 31.5% v two of 73 patients, 2.7%, respectively; P < .001; and after TKI: 10 of 12 patients, 83.3% v four of 12 patients, 33.3%, respectively; P = .0143). The EGFR mutations and their frequencies were confirmed by NGS. T790M was an independent predictor of decreased progression-free survival (PFS) in patients with NSCLC who received TKI treatment (P < .05, multivariate Cox regression). Conclusion: T790M may not be a rare event before or after TKI therapy in patients with NSCLC with EGFR-activating mutations. The pretreatment T790M mutation was associated with shorter PFS with EGFR TKI therapy in patients with NSCLC.
- 1 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (4) , 433-440
Top Cited PapersPretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Purpose: Patients with non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)–activating mutations have excellent response to EGFR tyrosine kinase inhibitors (TKIs), but T790M mutation accounts for most TKI drug resistance. This study used highly sensitive methods to detect T790M before and after TKI therapy and investigated the association of T790M and its mutation frequencies with clinical outcome. Patients and Methods: Direct sequencing, matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) and next-generation sequencing (NGS) were used to assess T790M in the following two cohorts of patients with NSCLC: TKI-naive patients (n = 107) and TKI-treated patients (n = 85). Results were correlated with TKI treatment response and survival. Results: MALDI-TOF MS was highly sensitive in detecting and quantifying the frequency of EGFR-activating mutations and T790M (detection limits, 0.4% to 2.2%). MALDI-TOF MS identified more T790M than direct sequencing in TKI-naive patients with NSCLC (27 of 107 patients, 25.2% v three of 107 patients, 2.8%, respectively; P < .001) and in TKI-treated patients (before TKI: 23 of 73 patients, 31.5% v two of 73 patients, 2.7%, respectively; P < .001; and after TKI: 10 of 12 patients, 83.3% v four of 12 patients, 33.3%, respectively; P = .0143). The EGFR mutations and their frequencies were confirmed by NGS. T790M was an independent predictor of decreased progression-free survival (PFS) in patients with NSCLC who received TKI treatment (P < .05, multivariate Cox regression). Conclusion: T790M may not be a rare event before or after TKI therapy in patients with NSCLC with EGFR-activating mutations. The pretreatment T790M mutation was associated with shorter PFS with EGFR TKI therapy in patients with NSCLC.
- Open Access
- 1 August 2011
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (8) , 3189-3205
The ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1
Metastasis is a predominant cause of death in patients with cancer. It is a complex multistep process that needs to be better understood if we are to develop new approaches to managing tumor metastasis. Tumor cell invasion of the local stroma is suppressed by collapsin response mediator protein-1 (CRMP-1). Recently, we identified a long isoform of CRMP-1 (LCRMP-1), expression of which correlates with cancer cell invasiveness and poor clinical outcome in patients with non-small-cell lung cancer (NSCLC). Here, we report that LCRMP-1 overexpression in noninvasive human cell lines enhanced filopodia formation, cancer cell migration, and invasion via stabilization of actin. This effect required a highly conserved N-terminal region of LCRMP-1 as well as the WASP family verprolin-homologous protein-1/actin nucleation pathway (WAVE-1/actin nucleation pathway). Furthermore, LCRMP-1 appeared to act downstream of Cdc42, a Rho family protein known to be involved in actin rearrangement. In addition, LCRMP-1 associated with CRMP-1, which downregulated cancer cell metastasis by interrupting the association of LCRMP-1 and WAVE-1. Finally, we found that high-level expression of LCRMP-1 and low-level expression of CRMP-1 were associated with lymph node metastasis and poor survival in patients with NSCLC. In sum, we show that LCRMP-1 and CRMP-1 have opposing functions in regulating cancer cell invasion and metastasis and propose that this pathway may serve as a potential anticancer target.
- 1 August 2011
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (8) , 3189-3205
Open AccessThe ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1
Metastasis is a predominant cause of death in patients with cancer. It is a complex multistep process that needs to be better understood if we are to develop new approaches to managing tumor metastasis. Tumor cell invasion of the local stroma is suppressed by collapsin response mediator protein-1 (CRMP-1). Recently, we identified a long isoform of CRMP-1 (LCRMP-1), expression of which correlates with cancer cell invasiveness and poor clinical outcome in patients with non-small-cell lung cancer (NSCLC). Here, we report that LCRMP-1 overexpression in noninvasive human cell lines enhanced filopodia formation, cancer cell migration, and invasion via stabilization of actin. This effect required a highly conserved N-terminal region of LCRMP-1 as well as the WASP family verprolin-homologous protein-1/actin nucleation pathway (WAVE-1/actin nucleation pathway). Furthermore, LCRMP-1 appeared to act downstream of Cdc42, a Rho family protein known to be involved in actin rearrangement. In addition, LCRMP-1 associated with CRMP-1, which downregulated cancer cell metastasis by interrupting the association of LCRMP-1 and WAVE-1. Finally, we found that high-level expression of LCRMP-1 and low-level expression of CRMP-1 were associated with lymph node metastasis and poor survival in patients with NSCLC. In sum, we show that LCRMP-1 and CRMP-1 have opposing functions in regulating cancer cell invasion and metastasis and propose that this pathway may serve as a potential anticancer target.
- 1 July 2011
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 32 (4) , 485-491
Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan
- 1 July 2011
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 32 (4) , 485-491
Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan
- Open Access
- 1 July 2009
- Published by Springer Nature in Nature Cell Biology
- Vol. 11 (7) , 914
Erratum: p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
- 1 July 2009
- Published by Springer Nature in Nature Cell Biology
- Vol. 11 (7) , 914
Open AccessErratum: p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
- 17 May 2009
- Published by Springer Nature in Nature Cell Biology
- Vol. 11 (6) , 694-704
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
The tumour suppressor p53 is known to prevent cancer progression by inhibiting proliferation and inducing apoptosis of tumour cells. Slug, an invasion promoter, exerts its effects by repressing E-cadherin transcription. Here we show that wild-type p53 (wtp53) suppresses cancer invasion by inducing Slug degradation, whereas mutant p53 may stabilize Slug protein. In non-small-cell lung cancer (NSCLC), mutation of p53 correlates with low MDM2, high Slug and low E-cadherin expression. This expression profile is associated with poor overall survival and short metastasis-free survival in patients with NSCLC. wtp53 upregulates MDM2 and forms a wtp53-MDM2-Slug complex that facilitates MDM2-mediated Slug degradation. Downregulation of Slug by wtp53 or MDM2 enhances E-cadherin expression and represses cancer cell invasiveness. In contrast, mutant p53 inactivates Slug degradation and leads to Slug accumulation and increased cancer cell invasiveness. Our findings indicate that wtp53 and p53 mutants may differentially control cancer invasion and metastasis through the p53-MDM2-Slug pathway.
- 17 May 2009
- Published by Springer Nature in Nature Cell Biology
- Vol. 11 (6) , 694-704
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
The tumour suppressor p53 is known to prevent cancer progression by inhibiting proliferation and inducing apoptosis of tumour cells. Slug, an invasion promoter, exerts its effects by repressing E-cadherin transcription. Here we show that wild-type p53 (wtp53) suppresses cancer invasion by inducing Slug degradation, whereas mutant p53 may stabilize Slug protein. In non-small-cell lung cancer (NSCLC), mutation of p53 correlates with low MDM2, high Slug and low E-cadherin expression. This expression profile is associated with poor overall survival and short metastasis-free survival in patients with NSCLC. wtp53 upregulates MDM2 and forms a wtp53-MDM2-Slug complex that facilitates MDM2-mediated Slug degradation. Downregulation of Slug by wtp53 or MDM2 enhances E-cadherin expression and represses cancer cell invasiveness. In contrast, mutant p53 inactivates Slug degradation and leads to Slug accumulation and increased cancer cell invasiveness. Our findings indicate that wtp53 and p53 mutants may differentially control cancer invasion and metastasis through the p53-MDM2-Slug pathway.
- 1 May 2009
- Published by Springer Nature in Drug Information Journal
- Vol. 43 (3) , 365-369
Nurturing the Clinical Research Leaders of Tomorrow
- 1 May 2009
- Published by Springer Nature in Drug Information Journal
- Vol. 43 (3) , 365-369
Nurturing the Clinical Research Leaders of Tomorrow
- 1 May 2009
- Published by Springer Nature in Drug Information Journal
- Vol. 43 (3) , 361-363
National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital
- 1 May 2009
- Published by Springer Nature in Drug Information Journal
- Vol. 43 (3) , 361-363
National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital